<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788580</url>
  </required_header>
  <id_info>
    <org_study_id>S0718</org_study_id>
    <secondary_id>SWOG-S0718</secondary_id>
    <nct_id>NCT00788580</nct_id>
  </id_info>
  <brief_title>S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>S0718: Phase I Study Evaluating The Combination of GW786034 (Pazopanib; NSC-737754; IND-XXXX) and CCI-779 (Temsirolimus; NSC-683864; IND-XXXX) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Pazopanib and temsirolimus may stop the growth of tumor cells by blocking some of&#xD;
      the enzymes needed for cell growth. Pazopanib may also blocking blood flow to the tumor.&#xD;
      Giving pazopanib together with temsirolimus may be an effective treatment for advanced solid&#xD;
      tumors.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of temsirolimus when&#xD;
      given together with pazopanib in treating patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To investigate the safety and feasibility of temsirolimus and pazopanib when given in&#xD;
           combination in patients with advanced solid tumors.&#xD;
&#xD;
        -  To recommend the maximum tolerated dose of this regimen in these patients.&#xD;
&#xD;
        -  To investigate the pharmacokinetics of temsirolimus alone and in combination with&#xD;
           pazopanib in these patients.&#xD;
&#xD;
        -  To investigate the effects of this regimen on relevant biological markers.&#xD;
&#xD;
        -  To preliminarily report objective response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive temsirolimus IV over 30 minutes on days 1, 8,15, and 22 and oral pazopanib&#xD;
      hydrochloride once daily on days 4-28 in course 1 and days 1-28 in all subsequent courses.&#xD;
      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are obtained periodically for evaluation of the pharmacokinetics of&#xD;
      temsirolimus and pazopanib, plasma and serum angiogenic and cachectic factors (e.g., VEGF,&#xD;
      bFGF, PlGF and SDF-1) by enzyme-linked immunosorbent assay, and biological markers in the&#xD;
      mTOR/PI3/Akt, Ras/MAPK, VEGFR, PDGFR, and HIF-1 pathways.&#xD;
&#xD;
      After completion of study therapy, patients are followed for 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was discontinued.&#xD;
  </why_stopped>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by NCI CTCAE v3.0</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of the drug combination</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of temsirolimus in combination with pazopanib</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of temsirolimus alone and in combination with pazopanib</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relevant biological markers</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response as assessed by RECIST criteria</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Cytologically or pathologically verified cancer that is of advanced stage and for&#xD;
             which there is no effective therapy&#xD;
&#xD;
               -  No lymphoma&#xD;
&#xD;
          -  Measurable or nonmeasurable disease&#xD;
&#xD;
          -  Previously irradiated (whole brain or gamma knife) brain metastases allowed provided&#xD;
             there is no requirement for corticosteroids or anticonvulsants&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Zubrod performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL (without transfusions)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN if liver metastases&#xD;
             present)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times ULN OR measured creatinine clearance OR calculated&#xD;
             creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  QTC interval &lt; 480 msec on baseline ECG OR average QTC &lt; 480 msec on baseline plus 2&#xD;
             additional screening ECG's&#xD;
&#xD;
          -  Fasting cholesterol &lt; 350 mg/dL&#xD;
&#xD;
          -  Fasting triglycerides &lt; 400 mg/dL&#xD;
&#xD;
          -  No uncontrolled hypertension, arterial thrombotic event, or bleeding on therapeutic&#xD;
             anticoagulation with warfarin or heparin (including low molecular weight heparin)&#xD;
             within the past 6 months&#xD;
&#xD;
          -  Able to swallow enteral medications&#xD;
&#xD;
          -  No feeding tubes&#xD;
&#xD;
          -  No intractable nausea or vomiting&#xD;
&#xD;
          -  No gastrointestinal (GI) tract disease resulting in an inability to take oral&#xD;
             medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical&#xD;
             procedures affecting absorption, or uncontrolled inflammatory GI disease (e.g., Crohn,&#xD;
             ulcerative colitis)&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to rapamycin analogs (e.g., sirolimus and everolimus)&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, the following:&#xD;
&#xD;
               -  Ongoing or serious active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Serious cardiac arrhythmia&#xD;
&#xD;
               -  History of myocardial infarction&#xD;
&#xD;
               -  Cerebrovascular accident within 3 months of study entry&#xD;
&#xD;
               -  Uncontrolled diarrhea&#xD;
&#xD;
               -  Psychiatric illness or social situation that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception, including barrier methods&#xD;
&#xD;
          -  Willing to undergo pharmacokinetic (PK) sampling and blood submission for PK and&#xD;
             translational medicine studies&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No prior pazopanib hydrochloride or temsirolimus&#xD;
&#xD;
          -  More than 28 days since prior major surgery, chemotherapy, biologic therapy, or&#xD;
             immunotherapy&#xD;
&#xD;
          -  More than 28 days since prior investigational agents&#xD;
&#xD;
          -  At least 14 days since prior radiotherapy&#xD;
&#xD;
          -  No concurrent rapamycin (sirolimus)&#xD;
&#xD;
          -  No concurrent enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or&#xD;
             phenobarbital), CYP3A4 inducers (e.g., rifampin or St. John's wort), or CYP3A4&#xD;
             inhibiting agents or substrates (e.g., ketoconazole, diltiazem, or verapamil)&#xD;
&#xD;
          -  No concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any&#xD;
             other type of therapy for treatment of this cancer while on this protocol&#xD;
&#xD;
               -  No live vaccines&#xD;
&#xD;
               -  Luteinizing-hormone releasing-hormone agonists allowed&#xD;
&#xD;
          -  Concurrent prophylactic warfarin (≤ 1 mg/day) allowed&#xD;
&#xD;
          -  Concurrent bisphosphonate or erythropoietin or its analogue allowed, if deemed&#xD;
             appropriate by the treating physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire F. Verschraegen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico Cancer Center</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>November 8, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

